文献速递膀胱癌与上尿路尿路上皮癌

根治性膀胱切除术后pN+膀胱癌患者中筛选最适合顺铂辅助化疗候选人的研究

Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2022-06-15

该多中心回顾性队列纳入1381例pTany pN1-3 cM0 R0尿路上皮膀胱癌根治性膀胱切除患者,391例(28%)接受顺铂辅助化疗。倾向评分匹配后281对患者分析显示,仅预后不良组(pTany且阳性淋巴结≥3枚)从辅助化疗中获得总生存获益(HR 0.51;p < 0.001)。

要点

  • CART分析将pN+患者分为预后良好(≤pT2且阳性淋巴结≤2枚;OR 0.43)、中等(≥pT3且阳性淋巴结≤2枚;OR 0.92)和不良(pTany且阳性淋巴结≥3枚;OR 1.36)三组。
  • 仅预后不良组从顺铂辅助化疗中获得总生存获益(HR 0.51;p < 0.001)。
  • pTany且阳性淋巴结≥3枚的患者被确定为顺铂辅助化疗的最合适候选人。

核心结论

  • 研究创建了首个将pN+膀胱癌患者分层为预后等级的算法,并确定pTany且阳性淋巴结≥3枚的患者为顺铂辅助化疗的最合适候选人。

研究设计与样本

  • 多中心回顾性队列研究,纳入1381例pTany pN1-3 cM0 R0尿路上皮膀胱癌接受根治性膀胱切除(伴或不伴顺铂辅助化疗)的患者,其中391例(28%)接受顺铂辅助化疗。
  • 采用1:1倾向评分匹配调整基线特征,匹配后获得281对pN+膀胱癌患者队列。
  • 采用分类与回归树(CART)分析评估术后风险组,采用Cox回归分析预测总生存(OS)。

主要发现

  • CART分析将患者分为三组:预后良好(≤pT2且阳性淋巴结计数≤2枚;OR 0.43)、中等预后(≥pT3且阳性淋巴结计数≤2枚;OR 0.92)和预后不良(pTany且阳性淋巴结计数≥3枚;OR 1.36)。
  • 仅预后不良组从辅助化疗中获得总生存获益(HR 0.51;p < 0.001)。

临床怎么用

  • 作者认为,pTany且阳性淋巴结≥3枚的pN+膀胱癌患者是顺铂辅助化疗的最合适候选人。
  • 作者指出,最高风险患者应优先接受膀胱切除术后顺铂辅助化疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A trend towards greater benefit from adjuvant chemotherapy (ACT) in pN+ bladder cancer (BCa) has been observed in multiple randomized controlled trials. However, it is still unclear which patients might benefit the most from this approach. We retrospectively analyzed a multicenter cohort of 1381 patients with pTany pN1-3 cM0 R0 urothelial BCa treated with radical cystectomy (RC) with or without cisplatin-based ACT. The main endpoint was overall survival (OS) after RC. We performed 1:1 propensity score matching to adjust for baseline characteristics and conducted a classification and regression tree (CART) analysis to assess postoperative risk groups and Cox regression analyses to predict OS. Overall, 391 patients (28%) received cisplatin-based ACT. After matching, two cohorts of 281 patients with pN+ BCa were obtained. CART analysis stratified patients into three risk groups: favorable prognosis (≤pT2 and positive lymph node [PLN] count ≤2; odds ratio [OR] 0.43), intermediate prognosis (≥pT3 and PLN count ≤2; OR 0.92), and poor prognosis (pTany and PLN count ≥3; OR 1.36). Only patients with poor prognosis benefitted from ACT in terms of OS (HR 0.51; p < 0.001). We created the first algorithm that stratifies patients with pN+ BCa into prognostic classes and identified patients with pTany BCa with PLN ≥3 as the most suitable candidates for cisplatin-based ACT. PATIENT SUMMARY: We found that overall survival among patients with bladder cancer and evidence of lymph node involvement depends on cancer stage and the number of positive lymph nodes. Patients with more than three nodes affected by metastases seem to experience the greatest overall survival benefit from cisplatin-based chemotherapy after bladder removal. Our study suggests that patients with the highest risk should be prioritized for cisplatin-based chemotherapy after bladder removal.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Afferi L, Lonati C, Montorsi F, et al. Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer. Eur Urol Oncol. 2022. PMID: 35715319. doi:10.1016/j.euo.2022.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。